Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the objective response rate (ORR) when panitumumab is
administered in combination with irinotecan as 2nd-line therapy in subjects with previously
treated metastatic colorectal cancer (mCRC).
Phase:
Phase 2
Details
Lead Sponsor:
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)